The provided abstract is truncated and does not contain the results of the CYCLE cohort study evaluating early rhythm control in acute decompensated heart failure.
Cohort
Rapid CommunicationAtrial fibrillation (AF) is common in patients with acute decompensated heart failure (HF).Both conditions share risk factors, e.g.hypertension, diabetes, coronary artery disease, and aggravate each other. 1 AF increases the risk of stroke, HF hospitalization, and mortality in acute decompensated HF. 2 Rhythm control in this population remains challenging due to frequent recurrences and limited therapeutic options.Early rhythm control reduces a composite outcome of cardiovascular death, stroke, or HF hospitalization by 21% compared with usual care in patients with AF and comorbidities, with consistent results in patients with AF and HF. 3,4 hile recent analyses indicate potential early benefits of rhythm control, the last randomized trial testing rhythm control in acute decompensated HF, ANDROMEDA, was halted nearly 20
Kriz et al. (Mon,) conducted a cohort in Acute decompensated heart failure and atrial fibrillation. Early rhythm control was evaluated. The provided abstract is truncated and does not contain the results of the CYCLE cohort study evaluating early rhythm control in acute decompensated heart failure.